VIR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-25), Vir Biotechnology's share price is $7.75. Vir Biotechnology's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.81. Hence, Vir Biotechnology's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Vir Biotechnology's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 7 years, Vir Biotechnology's highest Price-to-Operating-Cash-Flow Ratio was 6.06. The lowest was 1.57. And the median was 2.47.
Vir Biotechnology's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.80. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.81.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Vir Biotechnology was -147.10% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -53.60% per year.
During the past 7 years, Vir Biotechnology's highest 3-Year average Operating Cash Flow per Share Growth Rate was 28.40% per year. The lowest was -53.60% per year. And the median was -32.70% per year.
The historical data trend for Vir Biotechnology's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | 2.05 | - |
Vir Biotechnology Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | 2.05 | 3.13 | - | - | - |
For the Biotechnology subindustry, Vir Biotechnology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's Price-to-Operating-Cash-Flow falls into.
Vir Biotechnology's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 7.75 | / | -5.808 | |
= |
Vir Biotechnology's Share Price of today is $7.75.
Vir Biotechnology's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.81.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Vir Biotechnology's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008 |
Vicki L Sato | director | 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
Phillip Pang | officer: Chief Medical Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Steven J. Rice | officer: Chief Administrative Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Saira Ramasastry | director | 501 CANAL BLVD., RICHMOND CA 94804 |
Backer Marianne De | officer: Chief Executive Officer | 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105 |
Ann M. Hanly | officer: Chief Technology Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Sung Lee | officer: Chief Financial Officer | 7000 MARINA BLVD, BRISBANE CA 94005 |
Johanna Friedl-naderer | officer: Chief Business Officer, Global | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
George A Scangos | director, officer: President and CEO | C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083 |
Howard Horn | officer: CFO | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Charles Elliott Sigal | director | 32 BREARLY ROAD, PRINCETON NJ 08540 |
Herbert Virgin | officer: EVP, Research & CSO | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Janet Napolitano | director | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Robert J More | director | 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001 |
From GuruFocus
By sperokesalga sperokesalga • 05-03-2023
By sperokesalga sperokesalga • 05-17-2023
By sperokesalga sperokesalga • 06-07-2023
By Marketwired • 07-20-2023
By GuruFocus Research • 11-02-2023
By sperokesalga sperokesalga • 02-16-2023
By Business Wire • 11-13-2023
By Marketwired • 10-03-2023
By Marketwired • 08-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.